Table 7. Myelosuppression in the main randomized trials in first line.
|
Neutropenia |
Thrombocytopenia |
Anemia |
|||||
|---|---|---|---|---|---|---|---|
| All grades (%) | Grade ¾ (%) | All grades (%) | Grade 3/4 (%) | All grades (%) | Grade 3/4 (%) | ||
| ENESTND2 | Nilotinib 300 mg twice daily | 43 | 12 | 48 | 10 | 38 | 3 |
| Imatinib 400 mg daily | 68 | 20 | 56 | 9 | 47 | 5 | |
| DASISION4 | Dasatinib 100 mg daily | 65 | 21 | 70 | 19 | 90 | 10 |
| Imatinib 400 mg daily | 52 | 20 | 62 | 10 | 84 | 7 | |
| BELA22 | Bosutinib 500 mg daily | 28 | 11 | 66 | 14 | 80 | 6 |
| Imatinib 400 mg daily | 54 | 24 | 62 | 14 | 84 | 7 | |
Side effects, grading according to NCI-CTC (Common Terminology Criteria for Adverse Events of the National Cancer Institute).